This Baygam market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to a rise in immunoglobulin deficiencies, the increasing use of infectious disease prophylaxis, a growing geriatric population, heightened awareness of immune disorders, and the rising prevalence of chronic diseases.
Growth during the market's forecast period can be attributed to the growing adoption of immunoglobulin, the rising demand for advanced therapeutics for genetic disorder treatments, the increasing use of combination therapies, improved access to healthcare, and the growing prevalence of autoimmune and infectious diseases. Key trends in the forecast period include technological innovations, advancements in biologics and cell-based therapies, the integration of artificial intelligence in healthcare, ongoing developments in biotechnology, and the emergence of advanced therapeutics for treating genetic disorders.
The increasing prevalence of immunodeficiency diseases is expected to drive the growth of the baygam market in the future. Immunodeficiency diseases refer to conditions where the immune system is either absent or weakened, reducing its ability to combat infections and other diseases. The rising prevalence of these diseases is largely due to improved diagnosis and awareness, as well as an aging population with weakened immune systems, making them more susceptible to infections and immune disorders. Baygam supports patients with immunodeficiency diseases by providing intravenous immunoglobulin (IVIG) therapy, which replenishes vital antibodies in the body, enhancing the immune system’s ability to fight infections and decreasing the frequency and severity of bacterial and viral infections in individuals with compromised immune responses. For example, in June 2024, a report from the Australian Institute of Health and Welfare, a government organization, revealed that in 2021-22, there were 10,000 hospitalizations for rheumatoid arthritis, a 25% increase from the previous year’s 8,000, equating to a rate of 39 hospitalizations per 100,000 population. Therefore, the rising prevalence of immunodeficiency diseases is contributing to the expansion of the baygam market.
A key trend in the baygam market is the adoption of innovative solutions, such as immunoglobulin therapies, to address unmet medical needs and broaden treatment options for immune system disorders. Immunoglobulin therapies use antibodies derived from human plasma to treat various conditions, particularly those related to immune system deficiencies or disorders. For example, in February 2021, Hospital del Mar Medical Research Institute (IMIM), a Spain-based research organization, launched a clinical trial focused on utilizing immunoglobulin therapies to prevent side effects from COVID-19. This initiative is part of their ongoing research efforts to address COVID-19 impacts and involves collaboration with academic institutions such as the University of California-Davis and the University of Texas. The trial specifically investigates the use of bovine-derived immunoglobulins to reduce inflammation and improve patient outcomes related to COVID-19 symptoms.
In March 2023, Selagine, Inc., a US-based company developing novel therapeutics, formed a partnership with Grifols S.A., a Spain-based pharmaceutical company specializing in plasma-derived medicines. The collaboration aims to develop innovative immunoglobulin eye drops to treat dry eye disease (DED), leveraging Grifols' expertise in plasma-derived therapies and Selagine’s ocular treatment research to address a significant unmet medical need affecting over 100 million people worldwide.
The key company operating in the baygam market is Grifols S.A.
North America was the largest region in the baygam market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in baygam report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the baygam market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Baygam is a human rabies immunoglobulin (HRIG) used in post-exposure prophylaxis (PEP) for individuals who may have been exposed to the rabies virus. It is usually administered alongside the rabies vaccine to provide immediate passive immunity, while the body develops its own active immune response through the vaccination process.
The primary indications for baygam include primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and Guillain-Barré syndrome. Primary immunodeficiency refers to a group of disorders where the immune system is impaired from birth, leading to increased vulnerability to infections. Baygam is distributed through hospitals, clinics, and home care settings for various end users, including adults, geriatric patients, and children.
The baygam market research report is one of a series of new reports that provides baygam market statistics, including baygam industry global market size, regional shares, competitors with a baygam market share, detailed baygam market segments, market trends and opportunities, and any further data you may need to thrive in the baygam industry. This baygam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The baygam market consists of sales of products including imogam, hyperrab, kedrab, rabishield, and bayrab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to a rise in immunoglobulin deficiencies, the increasing use of infectious disease prophylaxis, a growing geriatric population, heightened awareness of immune disorders, and the rising prevalence of chronic diseases.
Growth during the market's forecast period can be attributed to the growing adoption of immunoglobulin, the rising demand for advanced therapeutics for genetic disorder treatments, the increasing use of combination therapies, improved access to healthcare, and the growing prevalence of autoimmune and infectious diseases. Key trends in the forecast period include technological innovations, advancements in biologics and cell-based therapies, the integration of artificial intelligence in healthcare, ongoing developments in biotechnology, and the emergence of advanced therapeutics for treating genetic disorders.
The increasing prevalence of immunodeficiency diseases is expected to drive the growth of the baygam market in the future. Immunodeficiency diseases refer to conditions where the immune system is either absent or weakened, reducing its ability to combat infections and other diseases. The rising prevalence of these diseases is largely due to improved diagnosis and awareness, as well as an aging population with weakened immune systems, making them more susceptible to infections and immune disorders. Baygam supports patients with immunodeficiency diseases by providing intravenous immunoglobulin (IVIG) therapy, which replenishes vital antibodies in the body, enhancing the immune system’s ability to fight infections and decreasing the frequency and severity of bacterial and viral infections in individuals with compromised immune responses. For example, in June 2024, a report from the Australian Institute of Health and Welfare, a government organization, revealed that in 2021-22, there were 10,000 hospitalizations for rheumatoid arthritis, a 25% increase from the previous year’s 8,000, equating to a rate of 39 hospitalizations per 100,000 population. Therefore, the rising prevalence of immunodeficiency diseases is contributing to the expansion of the baygam market.
A key trend in the baygam market is the adoption of innovative solutions, such as immunoglobulin therapies, to address unmet medical needs and broaden treatment options for immune system disorders. Immunoglobulin therapies use antibodies derived from human plasma to treat various conditions, particularly those related to immune system deficiencies or disorders. For example, in February 2021, Hospital del Mar Medical Research Institute (IMIM), a Spain-based research organization, launched a clinical trial focused on utilizing immunoglobulin therapies to prevent side effects from COVID-19. This initiative is part of their ongoing research efforts to address COVID-19 impacts and involves collaboration with academic institutions such as the University of California-Davis and the University of Texas. The trial specifically investigates the use of bovine-derived immunoglobulins to reduce inflammation and improve patient outcomes related to COVID-19 symptoms.
In March 2023, Selagine, Inc., a US-based company developing novel therapeutics, formed a partnership with Grifols S.A., a Spain-based pharmaceutical company specializing in plasma-derived medicines. The collaboration aims to develop innovative immunoglobulin eye drops to treat dry eye disease (DED), leveraging Grifols' expertise in plasma-derived therapies and Selagine’s ocular treatment research to address a significant unmet medical need affecting over 100 million people worldwide.
The key company operating in the baygam market is Grifols S.A.
North America was the largest region in the baygam market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in baygam report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the baygam market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Baygam is a human rabies immunoglobulin (HRIG) used in post-exposure prophylaxis (PEP) for individuals who may have been exposed to the rabies virus. It is usually administered alongside the rabies vaccine to provide immediate passive immunity, while the body develops its own active immune response through the vaccination process.
The primary indications for baygam include primary immunodeficiency, secondary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and Guillain-Barré syndrome. Primary immunodeficiency refers to a group of disorders where the immune system is impaired from birth, leading to increased vulnerability to infections. Baygam is distributed through hospitals, clinics, and home care settings for various end users, including adults, geriatric patients, and children.
The baygam market research report is one of a series of new reports that provides baygam market statistics, including baygam industry global market size, regional shares, competitors with a baygam market share, detailed baygam market segments, market trends and opportunities, and any further data you may need to thrive in the baygam industry. This baygam market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The baygam market consists of sales of products including imogam, hyperrab, kedrab, rabishield, and bayrab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Baygam Market Characteristics4. Baygam Market Trends and Strategies5. Baygam Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Baygam Pricing Analysis & Forecasts30. Global Baygam Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Baygam Market32. Recent Developments in the Baygam Market
3. Baygam Market Biologic Drug Characteristics
6. Global Baygam Growth Analysis and Strategic Analysis Framework
8. Baygam Market Segmentation
9. Global Baygam Epidemiology of Clinical Indications
10. Baygam Market Regional and Country Analysis
11. Asia-Pacific Baygam Market
12. China Baygam Market
13. India Baygam Market
14. Japan Baygam Market
15. Australia Baygam Market
16. South Korea Baygam Market
17. Western Europe Baygam Market
18. UK Baygam Market
19. Germany Baygam Market
20. France Baygam Market
21. Eastern Europe Baygam Market
22. North America Baygam Market
23. USA Baygam Market
24. Canada Baygam Market
25. South America Baygam Market
26. Middle East Baygam Market
27. Africa Baygam Market
28. Baygam Market Competitive Landscape and Company Profiles
29. Global Baygam Market Pipeline Analysis
33. Baygam Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Baygam Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on baygam market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for baygam? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The baygam market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Primary Immunodeficiency; Secondary Immunodeficiency; Chronic Inflammatory Demyelinating Polyneuropathy; Guillain-Barré Syndrome2) by Distribution Channel: Hospitals; Clinics; Homecare
3) by End User: Adult; Geriatric; Pediatric
Key Companies Mentioned: Grifols S.a
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Grifols S.A
